Shaily Engineering Plastics Ltd (SHAILY) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported strong performance in Q3 FY26, with a significant 27% year-on-year revenue growth and a notable 310 basis points expansion in EBITDA margin, driven by continued momentum across its business verticals.
- The Healthcare segment was the primary growth driver, with its contribution to the overall revenue mix doubling to 42% compared to the previous year, highlighting the successful scaling of this business.
- A major strategic milestone was the announcement of a new, scalable manufacturing facility in Abu Dhabi for pen and auto-injectors, a move designed to build capacity in the fast-growing drug delivery segment and position the company closer to its international clients.
- The company strengthened its healthcare leadership by appointing Mr. Joe Khan, with over 20 years of international experience in regulated industries, as the Chief Operating Officer of the Healthcare Division to drive operational excellence and support the next growth phase.
- While the Healthcare and Industrial segments showed robust growth, the Consumer segment experienced a decline, reflecting a broader demand slowdown in key export markets like Europe and the US.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.